Searched for
CHINESE DRUG MARKET
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Betting big on mid and smallcaps; largecaps most expensive on PEG basis, says Dinshaw IraniHelios Mutual Fund is shifting investments from large companies to mid and small companies. This move follows earnings growth trends where ...
- CEOs are getting ruthless about worker performanceCorporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volu...
- India losing investor attention to Asia’s AI-electronics surge, says DBS economistGlobal capital is shifting towards electronics and AI in Asia. India's foreign direct investment slowdown is not a major concern. Asia's ex...
- Weight-loss drug semaglutide set to get cheaper as generic wave builds in IndiaPrices for generic semaglutide, a popular weight-loss drug, are expected to fall by more than half in the coming months. This sharp decline...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Different packaging, typos expose fake Mounjaro racketGurugram authorities uncovered a counterfeit Mounjaro operation. Police seized fake diabetes and weight loss injections valued at ₹70 lakh....
- Obesity drug market to gain as Indians pop the pill and Chinese bring moreIndia's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...
- Govt's ammonia rule to hurt pharma cos as directive restricts sale of surplus to fertiliser firmsIndia’s pharmaceutical industry faces a potential raw material crunch after the government restricted surplus ammonia supply to fertiliser ...
- Semaglutide API price plunges amid GLP-1 rushGlobal demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...
- Large AI firms hoovering maximum funding, not enough for smaller startups: Y Combinator’s Ankit GuptaAnkit Gupta spoke to ET ahead of the accelerator’s Startup School event in Bengaluru on April 18 — the first in India. In order to tap aspi...
- China pulls ahead in biologics race, forcing Indian drugmakers to rethink strategyIndia's drug companies face a tough race in the global biologics market. China is quickly becoming a leader in biotech supply chains. India...
- Cipla, Natco Pharma, Hetero Labs among Indian firms chosen to supply key generic drugs in ChinaIndian firms Hetero Labs Limited, Cipla Ltd, Annora Pharma Private Limited and Natco Pharma won the bids conducted by the Chinese health mi...
- You thought only DeepSeek routed American titans? Wait, here's a little-known Chinese biotech company whose lung cancer drug could rattle big pharma; here's all about itChinese biotech company Akeso developed a lung cancer drug Ivonescimab, which outperformed Merck's Keytruda in trials. This breakthrough si...
- China's war on healthcare costs lures India's biggest drugmakerShanghvi believes market watchers are underestimating the potential in China for India’s largest drugmaker.
- Recalling defective vaccines will deal heavy blow to China's drug exports: expertsChina initiated protocols on Tuesday to recall fake rabies vaccines sold in other countries and regions amid the recent vaccine scandal.
- Bulk drugs from China floods Indian market, leaves indigenous products in dire straitsThe Indian bulk drug industry is in dire straits and their prospects appear bleak unless the government takes immediate steps to support th...
- USFDA vigilance on Chinese drug companies may benefit Indian counterpartsIndian drug makers see a significant business opportunity in the American regulator’s decision to step up vigilance on Chinese companies.
- Drug regulator bans raw material import from 10 Chinese firmsThe country’s drug regulator has banned import of raw material from 10 Chinese drug companies for supplying products without having the man...
- Ranbaxy ban to help Chinese companiesUS Food and Drug Administration’s ban on seven API products of Ranbaxy may turn out to be a boon for the company’s Chinese peers, according...
Load More
